Immatics N.V.
IMTX$1.33B
Small CapNASDAQBiotechnology🇺🇸North America645 employees
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IMTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
IMA203
Melanoma, Cutaneous Malignant
Sunitinib
Metastatic Renal Cell Carcinoma
IMA402 (Phase Ia)
Refractory Cancer
Endoxana, Leukine, IMA910
Colorectal Carcinoma
IMA203 Product
Refractory Cancer
Endoxana, IMA901, Leukine
Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMA203 | Phase 3 | Melanoma, Cutaneous Malignant | - | - |
Sunitinib | Phase 3 | Metastatic Renal Cell Carcinoma | - | - |
IMA402 (Phase Ia) | Phase 2 | Refractory Cancer | - | - |
Endoxana, Leukine, IMA910 | Phase 2 | Colorectal Carcinoma | - | - |
IMA203 Product | Phase 2 | Refractory Cancer | - | - |
Endoxana, IMA901, Leukine | Phase 2 | Renal Cell Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply